Furthermore, downregulation of NRP2 or upregulation of WDFY1 can promote cell death in metastatic cancer by controlling the signaling of VEGFRFs and maybe a potential target-based anticancer therapy [143]. The gene discussed is WDFY1; the disease is metastatic malignant neoplasm.